Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
Medical Dialogues8h
Roche, Zealand Pharma ink pact to co-develop, co-commercialise petrelintide as foundational therapy for obesity
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Devdiscourse19h
A Global Health System at a Crossroads: Innovations, Challenges, and Leadership Changes
Current health news highlights include Apollo Hospitals' AI investments to alleviate staff workload, Dr. Mehmet Oz's Medicare ...
The Dow drops almost 500 points and the S&P enters a correction as Trump tariffs rattle investors again
Stocks entered a correction on Thursday as the S&P 500 index fell 10% from its recent peak after President Donald Trump escalated the trade war with 200% tariffs on European alcoholic beverages. This ...